玻璃体腔注射Ranibizumab治疗高度近视黄斑区脉络膜新生血管疗效观察  

Therapeutic effect of intravitreal injection with Ranibizumab for highmyopic choroidal neovascularization

作　　者：毛羽佳[1] 杨媛媛[1] 何丽琴[1] 殷俏[1] 

机构地区：[1]南昌大学上饶医院眼科,江西上饶334000

出　　处：《中国现代医生》2015年第31期55-57,F0003,共4页China Modern Doctor

摘　　要：目的观察玻璃体腔注射抗血管内皮生长因子单克隆抗体Ranibizumab治疗高度近视黄斑区脉络膜新生血管（CNV）的近期临床疗效及安全性。方法将我院眼科中心2012年8月～2014年8月就诊的高度近视CNV患者20例20只眼纳入研究。测量最佳矫正视力（BCVA）、眼压、眼底照相、荧光眼底血管造影（FFA）及光学相干断层扫描（OCT）。所有患眼行玻璃体腔注射Ranibizumab 0．05mL。治疗后第1、2、3、6个月各随访1次，对比分析BCVA及黄斑中心凹视网膜厚度（CMT）变化情况。结果末次随访时平均玻璃体腔注射次数（1．7±0．5）针，BCVA较治疗前提高（0．36±0．12）LogMAR，差异有统计学意义（t=2．511，P〈0.05）。CMT降低（78．60±25．38）μm，差异有统计学意义（t=5．021，P〈0.05）。术后及随访期间未发生眼部及全身严重不良反应。结论玻璃体腔注射Ranibizumab治疗高度近视黄斑区脉络膜新生血管视力预后好，视网膜水肿消退明显，安全有效。Objective To observe the safety and efficacy of intraviteal injection of Ranibizumab for the treatment of higemyopic choroidal neovascularization（MCNV）. Methods A total of 20 eyes of 20 patients with MCNV were collected from August 2012 to August 2014. All cases were treated with intravitreal injection of 0.05 mL of Ranibizumab, and were taken best-corrected visual acuity（BCVA）, intraocular pressure, fundus photography, fundus fluorescein angiography （FFA） and optical coherence tomography（OCT） before treatment and at every follow-up visit at 1, 2, 3, 6 months. The changes of BCVA and central macular thickness（CMT） were observed. Results At the last follow-up, all the eyes were treated with intravitreal injection for （1.7±0.5） times, the BCVA improved （0.36±0.12） Log MAR, the difference was statistically significant （t=2.511, P〈0.05）; CMT decreased （78.60±25.38） μm, the difference was statistically significant （t=5.021, P〈0.05）. No ocular adverse events or serious systemic were noticed. Conclusion Intravitreal injection of Ranibizumab for the treatment of higemyopic choroidal neovascularization showed visual acuity improvement, retinal thickness reduction and safety.

关 键 词：高度近视 脉络膜新生血管 玻璃体腔注射 RANIBIZUMAB 最佳矫正视力 黄斑中心凹厚度 

分 类 号：R778.1[医药卫生—眼科] R774.5[医药卫生—临床医学]